October 3, 2024
FDA grants fast track status for Volastra’s VLS-1488 to treat ovarian cancer
The US Food and Drug Administration (FDA) has granted fast track designation for Volastra Therapeutics’ KIF18A inhibitor, VLS-1488, to treat patients with platinum-resistant high-grade serous ovarian cancer (HGSOC).